Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Changzhou No.2 People's Hospital
Celtic Biotech Ltd
BigHat Biosciences, Inc.
Dartsbio Pharmaceuticals Ltd.
Curtin University
Hospices Civils de Lyon
University of Arizona
Centre Leon Berard
State University of Londrina
Fred Hutchinson Cancer Center
Johnson & Johnson Enterprise Innovation Inc.
University of Pittsburgh
Rabin Medical Center
Kexing Biopharm Co., Ltd.
University of Rochester
UNC Lineberger Comprehensive Cancer Center
Centre hospitalier de l'Université de Montréal (CHUM)
Biocon Limited
Rabin Medical Center
The Hong Kong Polytechnic University
Yale University
Recurv Pharma Inc
Vanderbilt-Ingram Cancer Center
University of Kentucky
Tianjin Medical University Cancer Institute and Hospital
LARKSPUR BIOSCIENCES, INC.
State University of Londrina
Wake Forest University Health Sciences
Duke University
Regeneron Pharmaceuticals
Vanderbilt-Ingram Cancer Center
Centre Oscar Lambret
Rutgers, The State University of New Jersey
University Health Network, Toronto
University of Florida
The University of Hong Kong
Inova Health Care Services
AstraZeneca
Protara Therapeutics
Ain Shams University
VA Office of Research and Development
Peking University
WestVac Biopharma Co., Ltd.
Washington University School of Medicine
Coherence Neuro Australia Pty Limited
University of Alabama at Birmingham
Relmada Therapeutics, Inc.
Drexel University